1. 152OEfficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib. (25th November 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J-F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 67PPooled safety analysis of tepotinib in Asian patients with advanced solid tumours. (24th November 2019) Authors: Yamazaki, K; Ryoo, B-Y; Doi, T; Paik, P K; Veillon, R; Decaens, T; Faivre, S; Falchook, G S; Hong, D S; Scheele, J; Bruns, R; Berghoff, K; Qin, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 698PPhase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC). (23rd October 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma. (25th October 2018) Authors: Raoul, J L; Faivre, S; Frenel, J S; Rimassa, L Journal: Annals of oncology Issue: Volume 30:Number 1(2019) Page Start: 6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗